Who Paid My Doc
Ocrelizumab in Patients With RMS
Research payments
$9,114,181
Through program year 2025, $9,114,181 in research payments was reported against Ocrelizumab in Patients With RMS, across 1,136 payments, paid by F. Hoffmann-La Roche AG.
- Paid by
- F. Hoffmann-La Roche AG
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $19,502 | 8 |
| 2024 | Research | $32,061 | 20 |
| 2023 | Research | $1,311,077 | 342 |
| 2022 | Research | $1,816,167 | 181 |
| 2021 | Research | $1,498,756 | 199 |
| 2020 | Research | $1,895,336 | 191 |
| 2019 | Research | $2,541,283 | 195 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Robert Naismith Saint Louis, MO Named on 104 payments
- Bruce Cree San Francisco, CA Named on 58 payments
- Gabriel Pardo Oklahoma City, OK Named on 43 payments
- Ben Thrower Atlanta, GA Named on 35 payments
- Bhupesh Dihenia Lubbock, TX Named on 33 payments
- Daniel Wynn Northbrook, IL Named on 30 payments
- Derrick Robertson Tampa, FL Named on 28 payments
- Andrew Solomon Burlington, VT Named on 27 payments
- Jessica Stulc Golden Valley, MN Named on 26 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.